An analysis of the duplicate testing strategy of an Irish immunochemical faecal occult blood test colorectal cancer screening programme

Colorectal Disease

Volumn 15, Issue 9, 2013, Pages

  Kelley, L ^a   Swan, N ^a,c   Hughes, D J ^b  

^a ADELAIDE AND MEATH HOSPITAL   (Ireland)

^b ROYAL COLLEGE OF SURGEONS IN IRELAND   (Ireland)

^c ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

Author keywords

Advanced adenomas; Cancer screening; Colorectal cancer; Immunochemical faecal occult blood test

Indexed keywords

HEMOGLOBIN;

ADENOMATOUS POLYP; ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER SCREENING; COLON DIVERTICULOSIS; COLONOSCOPY; COLORECTAL ADENOMA; COLORECTAL CANCER; COLORECTAL CARCINOMA; COLORECTAL POLYP; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DUPLICATE IMMUNOCHEMICAL FAECAL OCCULT BLOOD TEST; ENDOCRINE TUMOR; ENTERITIS; FEMALE; HEMOGLOBIN BLOOD LEVEL; HEMORRHOID; HUMAN; IMMUNOCHEMISTRY; IMMUNOSENSOR; IRELAND; MAJOR CLINICAL STUDY; MALE; OCCULT BLOOD TEST; PILOT STUDY; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; VILLOUS ADENOMA;

ADVANCED ADENOMAS; CANCER SCREENING; COLORECTAL CANCER; IMMUNOCHEMICAL FAECAL OCCULT BLOOD TEST;

ADENOMA; AGED; CARCINOMA; COLONOSCOPY; COLORECTAL NEOPLASMS; EARLY DETECTION OF CANCER; FEMALE; HUMANS; IMMUNOCHEMISTRY; IRELAND; MALE; MIDDLE AGED; OCCULT BLOOD; PILOT PROJECTS;

EID: 84884728086     PISSN: 14628910     EISSN: 14631318     Source Type: Journal    
DOI: 10.1111/codi.12310     Document Type: Article

References (37)

1. O'Lorcain P, Deady S, Comber H. Mortality predictions for colon and anorectal cancer for Ireland, 2003-17. Colorectal Dis 2006; 8: 393-401.
2. Towler B, Irwig L, Glasziou P, Kewenter J, Weller D, Silagy C. A systematic review of the effects of screening for colorectal cancer using the faecal occult blood test, hemoccult. BMJ 1998; 317: 559-65.
3. Mandel JS, Church TR, Bond JH et al. The effect of fecal occult-blood screening on the incidence of colorectal cancer. N Engl J Med 2000; 343: 1603-7.
4. Lindholm E, Brevinge H, Haglind E. Survival benefit in a randomized clinical trial of faecal occult blood screening for colorectal cancer. Br J Surg 2008; 95: 1029-36.
5. Fraser CG. Faecal occult blood tests - eliminate, enhance or update? Ann Clin Biochem 2008; 45: 117-21.
6. Federici A, Giorgi Rossi P, Borgia P, Bartolozzi F, Farchi S, Gausticchi G. The immunochemical faecal occult blood test leads to higher compliance than the guaiac for colorectal cancer screening programmes: a cluster randomized controlled trial. J Med Screen 2005; 12: 83-8.
7. Hoffman RM, Steel S, Yee EF, Massie L, Schrader RM, Murata GH. Colorectal cancer screening adherence is higher with fecal immunochemical tests than guaiac-based fecal occult blood tests: a randomized, controlled trial. Prev Med 2010; 50: 297-9.
8. van Rossum LG, van Rijn AF, Laheij RJ et al. Random comparison of guaiac and immunochemical fecal occult blood tests for colorectal cancer in a screening population. Gastroenterology 2008; 135: 82-90.
9. van Rossum LG, van Rijn AF, Verbeek AL et al. Colorectal cancer screening comparing no screening, immunochemical and guaiac fecal occult blood tests: a cost-effectiveness analysis. Int J Cancer 2011; 128: 1908-17.
10. Heresbach D, Chauvin P, Grolier J, Josselin JM. Cost-effectiveness of colorectal cancer screening with computed tomography colonography or fecal blood tests. Eur J Gastroenterol Hepatol 2009; 22: 1372-9.
11. Zhu MM, Xu XT, Nie F, Tong JL, Xiao SD, Ran ZH. Comparison of immunochemical and guaiac-based fecal occult blood test in screening and surveillance for advanced colorectal neoplasms: a meta-analysis. J Dig Dis 2010; 11: 148-60.
12. Guittet L, Bouvier V, Mariotte N et al. Comparison of a guaiac based and an immunochemical faecal occult blood test in screening for colorectal cancer in a general average risk population. Gut 2007; 56: 210-4.
13. Ciatto S, Martinelli F, Castiglione G et al. Association of FOBT-assessed faecal Hb content with colonic lesions detected in the Florence screening programme. Br J Cancer 2007; 96: 218-21.
14. Dancourt V, Lejeune C, Lepage C, Gailliard MC, Meny B, Faivre J. Immunochemical faecal occult blood tests are superior to guaiac-based tests for the detection of colorectal neoplasms. Eur J Cancer 2008; 44: 2254-8.
15. Hol L, Wilschut JA, van Ballegooijen M et al. Screening for colorectal cancer: random comparison of guaiac and immunochemical faecal occult blood testing at different cut-off levels. Br J Cancer 2009; 100: 1103-10.
16. McNamara D, Qasim A, Lee N, Condon C, O'Morain C. Round one of the Adelaide and Meath Hospital/Trinity College Colorectal Cancer Screening Programme: programme report and analysis based on established international key performance indices. Ir J Med Sci 2011; 180: 549-52.
17. Levi Z, Rozen P, Hazazi R et al. A quantitative immunochemical fecal occult blood test for colorectal neoplasia. Ann Intern Med 2007; 146: 244-55.
18. Castiglione G, Grazzini G, Miccinesi G et al. Basic variables at different positivity thresholds of a quantitative immunochemical test for faecal occult blood. J Med Screen 2002; 9: 99-103.
19. Rubeca T, Rapi S, Confortini M et al. Evaluation of diagnostic accuracy of screening by fecal occult blood testing (FOBT). Comparison of FOB Gold and OC Sensor assays in a consecutive prospective screening series. Int J Biol Markers 2006; 21: 157-61.
20. Grazzini G, Castiglione G, Ciabattoni C et al. Colorectal cancer screening programme by faecal occult blood test in Tuscany: first round results. Eur J Cancer Prev 2004; 13: 19-26.
21. Grazzini G, Visioli CB, Zorzi M et al. Immunochemical faecal occult blood test: number of samples and positivity cutoff. What is the best strategy for colorectal cancer screening? Br J Cancer 2009; 100: 259-65.
22. Kim DH, Pickhardt PJ, Taylor AJ et al. CT colonography versus colonoscopy for the detection of advanced neoplasia. N Engl J Med 2007; 357: 1403-12.
23. Winawer SJ, Zauber AG. The advanced adenoma as the primary target of screening. Gastrointest Endosc Clin N Am 2002; 12: 1-9.
24. O'Connell JB, Maggard MA, Ko CY. Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging. J Natl Cancer Inst 2004; 96: 1420-5.
25. Schlemper RJ, Riddell RH, Kato Y et al. The Vienna classification of gastrointestinal epithelial neoplasia. Gut 2000; 47: 251-5.
26. van Rossum LG, van Rijn AF, Laheij RJ et al. Cutoff value determines the performance of a semi-quantitative immunochemical faecal occult blood test in a colorectal cancer screening programme. Br J Cancer 2009; 101: 1274-81.
27. Brecht JG, Robra BP. A graphic method of estimating the specificity of screening programmes from incomplete follow-up data. Methods Inf Med 1987; 26: 53-8.
28. Kolligs FT, Crispin A, Munte A, Wagner A, Mansmann U, Goke B. Risk of advanced colorectal neoplasia according to age and gender. PLoS ONE 2011; 6: e20076.
29. Guittet L, Guillaume E, Levillain R et al. Analytical comparison of three quantitative immunochemical fecal occult blood tests for colorectal cancer screening. Cancer Epidemiol Biomarkers Prev 2011; 20: 1-10.
30. Shuhaibar M, Walsh C, Lindsay F et al. A comparative study of faecal occult blood kits in a colorectal cancer screening program in a cohort of healthy construction workers. Ir J Med Sci 2011; 180: 103-8.
31. Lee CS, O'Gorman P, Walsh P et al. Immunochemical faecal occult blood tests have superior stability and analytical performance characteristics over guaiac-based tests in a controlled in vitro study. J Clin Pathol 2011; 64: 524-8.
32. Goede SL, van Roon AH, Reijerink JC et al. Cost-effectiveness of one versus two sample faecal immunochemical testing for colorectal cancer screening. Gut 2013; 62: 727-34.
33. Chen LS, Liao CS, Chang SH, Lai HC, Chen TH. Cost-effectiveness analysis for determining optimal cut-off of immunochemical faecal occult blood test for population-based colorectal cancer screening (KCIS 16). J Med Screen 2007; 14: 191-9.
34. Guittet L, Bouvier V, Mariotte N et al. Performance of immunochemical faecal occult blood test in colorectal cancer screening in average-risk population according to positivity threshold and number of samples. Int J Cancer 2009; 125: 1127-33.
35. Terhaar sive Droste JS, Oort FA, van der Hulst RW et al. Higher fecal immunochemical test cutoff levels: lower positivity rates but still acceptable detection rates for early-stage colorectal cancers. Cancer Epidemiol Biomarkers Prev 2011; 20: 272-80.
36. Rozen P, Comaneshter D, Levi Z et al. Cumulative evaluation of a quantitative immunochemical fecal occult blood test to determine its optimal clinical use. Cancer 2010; 116: 2115-25.
37. Hol L, Van Leerdam ME, Van Ballegooijen M et al. Screening for colorectal cancer; randomised trial comparing guaiac-based and immunochemical faecal occult blood testing and flexible sigmoidoscopy. Gut 2010; 59: 62-8.